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Mathematical modeling techniques have been widely employed to understand how cancer grows, and, more recently, such
approaches have been used to understand how cancer can be controlled. In this manuscript, a previously validated hybrid
cellular automaton model of tumor growth in a vascularized environment is used to study the antitumor activity of several
vascular-targeting compounds of known eﬃcacy. In particular, this model is used to test the antitumor activity of a clinically
used angiogenesis inhibitor (both in isolation, and with a cytotoxic chemotherapeutic) and a vascular disrupting agent
currently undergoing clinical trial testing. I demonstrate that the mathematical model can make predictions in agreement with
preclinical/clinical data and can also be used to gain more insight into these treatment protocols. The results presented herein
suggest that vascular-targeting agents, as currently administered, cannot lead to cancer eradication, although a highly eﬃcacious
agent may lead to long-term cancer control.
1.Introduction
Solid tumors require a functioning vasculature for the
delivery of oxygen and nutrients, as well as for the removal
of toxic waste products associated with cellular metabolism.
A tumor can partially ﬁll its vascular needs via the cooption
(incorporation) of existing host blood vessels. However,
tumor growth beyond a microscopic size and cancer cell
metastasis both depend on the recruitment of new blood
vessels to the tumor via a process called angiogenesis [1].
The angiogenicprocess is inﬂuenced byendogenouspro-
and antiangiogenic molecules, as well as biophysical triggers,
including metabolic and mechanical stress [1]. It is said that
the angiogenic switch is “on” when the net eﬀect of the pro-
and antiangiogenic triggers is tipped in favor of angiogenesis
and that the switch is “oﬀ” when the balance is tipped in the
other direction [1, 2].
The growth of new blood vessels via angiogenesis invari-
ably lags behind tumor growth. This results in a tumor vas-
culature that is morphologically and functionally abnormal
and, hence,diﬀersgreatly fromthenormal adultvasculature.
In particular, the angiogenic vasculature is leaky (as the ves-
sels contain many openings), consists of many dilated vessels
with varying diameter, and is highly tortuous, making blood
ﬂow through angiogenic vessels chaotic [1, 3]. Furthermore,
tumor vessels tend to proliferate faster and express diﬀerent
proteins than the normal vasculature [4]. Taken together,
these abnormal traits of the tumor vasculature allow it to
be directly targeted with drugs without a signiﬁcant risk of
interfering with the normal vasculature [3, 4].
Vascular-targeting therapies aim to take advantage of
unique features of the vascular network in tumors. These
treatments fall into two general categories. The ﬁrst is the
angiogenesis inhibitors (AIs), which attempt to inhibit the
tumor-initiated angiogenic process in order to prevent the
formation of new blood vessels. AIs have been developed
that inhibit proangiogenic molecules, bind to angiogenic
receptors, inhibit the proliferation of the endothelial cells
(ECs) that make up blood vessels, and upregulate/deliver
antiangiogenic compounds [1, 3]. AIs are not intended to
directly kill a tumor, but indirect growth inhibition and
metastasis prevention are expected as the tumor cannot2 Computational and Mathematical Methods in Medicine
develop the vasculature required to maintain active growth
and spread. Given the indirect mode of action of AIs, they
are typically administered chronically over months and years
[3].
A number of AIs are currently being tested in clinical
trials as either stand-alone cancer therapies or in combina-
tion with traditional therapeutic modalities. A search at the
National Cancer Institute’s website (http://www.cancer.gov/
clinicaltrials/search/) for “all cancers,” “treatment,” and “all
countries” returns 1312 clinical trials involving antiangio-
genesis compounds. A similar search on http://clinicaltrials
.gov/ returns 106 clinical trials involving antiangiogenesis
compounds. One AI, bevacizumab (Avastin), has been
approved by the U.S. Food and Drug Administration (FDA)
for use with other drugs to treat colorectal, lung, breast,
brain, and kidneycancer[5].Althoughbevacizumabhas had
transient eﬀects in many patients and, therefore, increases
progression-free survival, the long-term eﬀects of the drug
are more sobering. While many patients’ exhibit an ini-
tial period of growth inhibition, tumor regrowth almost
inevitably occurs after several months of treatment [5].
The second approach to targeting the vasculature
involves the use of vascular disrupting agents (VDAs) that
attempt to cause rapid and selective shutdown of tumor-
associated blood vessels [3, 4]. VDAs are expected to cause
cancer cell death as a result of blocking oﬀ at u m o r ’ s
blood supply. VDAs achieve their selectivity for tumor-
associated vessels through either ligand selectivity (i.e.,
selectively binding to unique angiogenic vessel receptors) or
physiological selectivity [4]. Given that VDAs are expected
to cause rapid shutdown of the tumor vasculature, drugs
that fall into this category are designed to be used in an
intermittent fashion rather than over the long-term [1].
Preclinical studies have shown that VDAs can enhance
the eﬃcacy of chemotherapy, radiation, and even antiangio-
genic agents [4]. Despite the successes of preclinical trials,
VDAs have not gained as much momentum as AIs in the
clinical realm. A search at the National Cancer Institute’s
website (http://www.cancer.gov/clinicaltrials/search/)for“all
cancers,” “treatment,” and “all countries” only brings up 1
VDA that is currently in clinical trials. A similar search on
http://clinicaltrials.gov/ returns 13 clinical trials involving
vascular disrupting agents. VDAs may be poorly represented
in the clinical trial pool because while they can trigger tumor
death in about 95% of a tumor mass, tumor cells tend to
survive at a thin rim on the tumor periphery. This thin rim
of surviving cells can eventually repopulate the mass, leading
to tumor regrowth [4].
The large number of vascular-targeting compounds that
arebeingconsideredforuseinpatientsrepresentsanexciting
time for those in the ﬁeld of angiogenesis research. At the
same time, the discovery and development of a new drug
is a time consuming and incredibly expensive undertaking.
The time between preclinical testing of a compound and
approval of a New Drug Application has been shown to take
anywhere between 3.2 and 20years, which an averagetime of
about 8.5 years [6]. Further, it has been estimated that in the
years 1989–2002, the ﬁnal cost of developing a cancer drug
averaged $1.04 billion [7]. On top of these exorbitant time
and monetary costs, it is estimated that only 21.5% of drugs
that complete a phase III clinical trial gain approval to be
produced and marketed as a new drug [6]. Thus, given the
amount of time and money it takes to develop a new drug,
along with the risks of failure, pharmaceutical companies are
trying to decide as early in the process as possible whether to
proceed with or abandon testing a new drug.
A relatively novel method to evaluate the potential eﬃ-
cacy of a new compound is through mathematical/compu-
tational modeling. Experimentally validated mathematical
modelsallow one totest theeﬃcacy ofadrug atanextremely
minimal time and ﬁnancial cost. In this manuscript, I
have used a previously validated hybrid cellular automaton
model of tumor growth to demonstrate the power in silico
techniques have to make predictions on the antitumor
activity ofcancerdrugs. The strengths and weaknesses ofthis
computer-based method are discussed, and implications for
the drug development process are explored.
2.PreviousWork
Theuseofmathematicaltechniquesinthedrugdevelopment
process is not a novel one. Pharmacokinetic (PK) and
pharmacodynamic (PD) models have been utilized for
decadestodeterminetherelationship betweendrugdoseand
response. In particular, PK models study what the body does
to a drug,includingmechanisms ofdrugabsorption and dis-
tribution (typically modeled through diﬀerential equations)
and duration of drug eﬀect [8]. On the other hand, PD
models study the relationship between drug concentration
and it physiological eﬀects on the body. Typically, drug-
receptor interactions are modeled via a system of diﬀerential
equations [8]. By coupling PK and PD models, one can
understand both a drug’s eﬀects on the body (at least the
receptor level) and the bodies eﬀects on a drug. PK/PD
modeling has become increasingly important in the drug
development process, being used in preclinical trials to
support drug discovery, to interpret toxicity data [8], and to
determine optimal dosing strategies [9–12].
Mathematics has been employed in other ways to study
tumor response to drugadministration. While a comprehen-
sivediscussionoftheseapproachesisbeyondthescopeofthis
paper, it is worthwhile to mention a number of interesting
models that have been developed to understand tumor drug
response. Chemotherapy, for example, has been extensively
studied using mathematical models. Some of these models
focus on the predicted eﬃcacy of a chemotherapeutic
treatment regime [13–15], its dependence on the immune
system [16], the transport of chemotherapeutic agents [17–
19], the development of drug resistance [20–23], and, as
previously mentioned, optimisation of scheduling protocols
[9–12, 16, 24].
Recently, PK/PD models have been coupled with models
of tumor growth in order to explore drug dynamics and the
resulting impact on tumor growth rates [14, 25]. In partic-
ular, in [14], the authors developed and coupled a PK/PD
model of a chemotherapeutic agent called Doxorubicin with
a model of non-Hodgkin’s lymphoma (a nonsolid tumor)Computational and Mathematical Methods in Medicine 3
progression. Using the mathematical model, predictions
were made on the eﬃcacy of Doxorubicin in patients with
high-grade, intermediate-grade, and low-grade non-Hodg-
kin’s lymphoma [14].
While the work done in [14] focused on nonsolid
tumors, PK/PD models have been merged with models of
solid tumor growth as well [25]. In particular, in [25], the
authors grew in silico tumors via an experimentally validated
multiscale model of tumor growth and angiogenesis. Once
the tumors were grown, a multicompartment PK model was
used to simulate chemotherapeutic agent administration. A
PD model was then utilized to determine the fraction of cells
whose growth was inhibited by the administration of each of
the chemotherapeutic agents [25]. The novelty in this work
lies in merging standard PK/PD modeling approaches with
computer-based tumor growth models, allowing levels of
tumorcellinhibitiontobedetermined.Inthisway,theshort-
term eﬀects of a drug on cancer growth can be predicted.
A strength of the aforementioned model is its ability to
predict drug eﬀects that are consistent with experimental
data. However, the model does not look at the long-term
eﬀects of drug therapy. Long-term eﬀects of cancer drug
therapy have been explored elsewhere [26, 27]. In particular,
in [26], the authors developed a nonlinear system of partial
diﬀerential equations to study the continuous infusion of
blood-borne chemotherapeutic agents that either target
proliferating cells, a proangiogenic factor, or the tumor vas-
culature [26]. Tumor growth was compared before and after
therapy, allowing the eﬀects of diﬀerent chemotherapeutic
agents to be studied. In [27], a reaction-diﬀusion model that
accounts for tumor-host interactions was utilized to test the
impact of diﬀerent chemotherapeutic regimes, including an
AIand a cytotoxicdrug that targetsproliferating cancercells.
Based on the simulated spatial distribution of normoxic and
hypoxic cancer cells after treatment, the capabilities of these
drugs to reduce tumor mass and invasion were quantiﬁed
[27]. Both of these works provide an example of how a
mathematical model can be used to determine the long-term
impact a drug has on tumor growth and survival.
The aforementioned models all represent progress in
the direction of computer-aided drug development. To
my knowledge, all models of solid tumor growth that
have been developed for this purpose considered tumors
that grow in avascular environments. On the other hand,
a number of malignancies, including brain cancer, grow
in vascular environments. Given the important role the
tumor microenvironment plays in treatment response, it is
important to expand the modeling work to include tumors
that grow in well-vascularized environments.
3.MathematicalModel
3.1. Hybrid CA Model of Vascular Tumor Growth. The math-
ematical model I will utilize to test tumor response to
an array of vascular-targeting therapies was developed to
simulate the growth of a particular type of brain cancer
called glioblastoma multiforme (GBM). GBM is the most
aggressive of the gliomas, a collection of tumors arising from
theglialcellsortheirprecursorsinthecentralnervoussystem
[28].Despiteadvances madeincancertreatment, themedian
survival time for a patient diagnosed with GBM is currently
between12and15months[29].Whilethisprognosisisgrim,
this median represents a signiﬁcant improvement over the
2001 median survival time, which was only eight months
[30].
Despite some measurable improvements in GBM sur-
vival times, the disease is almost uniformly fatal. In order to
understand what is unique about GBM that enables it
to successfully evade treatment, Kansal et al. developed a
cellular automaton (CA) model of GBM growth. In this
CA algorithm, it was shown that three-dimensional tumor
growth and composition can be realistically predicted by a
simple set of automaton rules and a set of four microscopic
parameters that account for the nutritional needs of the
tumor, cell-doubling time, and an imposed spherical sym-
metry term [31].
The success of this CA model is in part related to its
simplicity, and one of the simplifying assumptions is that
the vasculature is implicitly present and evolves as the tumor
grows. In order to incorporate a higher level of biological
realism into the original CA algorithm, a two-dimensional
hybrid cellular automaton model was developed to explore
the feedback that occurs between a growing tumor and the
evolving host blood supply [32]. Again, it is important to
note here that the model is built under the assumption that a
tumoris growing in awell-vascularized environment, likethe
brain.
For tumors growing in a vascularized environment, the
cooption-regression-growth experimental model of tumor
vasculature evolutionhas been proposed [33]. In this model,
as a tumorous mass grows, the cancer cells coopt the mature
blood vessels of the surrounding tissue. Given that the
coopted vessels were part of the regular vasculature that
provides healthy tissue with oxygen and nutrients, these
vessels are generally mature and stable. While many proteins
contribute to this phenotype of the normal vasculature,
angiopoietin-1 (Ang-1) is constitutivelyexpressed by normal
blood vessels and plays an important role in vessel maturity
and stabilization [34].
As a tumor mass grows and coopts the blood vessels of
healthy tissue, the naturally-occurring antagonist of Ang-1,
angiopoietin-2 (Ang-2) is thought to be upregulated by both
the tumorand the surrounding microenvironment [33].The
fact that Ang-2 is an antagonist to Ang-1 means the two
proteins compete for binding to a common receptor, in this
case Tie-2. Given that Ang-2 limits the action of Ang-1, Ang-
2i sr e s p o n s i b l ef o rt h edestabilization of the vasculature [33].
The fate of an unstable blood vessel depends on the pres-
ence of a third protein, vascular endothelial growth factor
(VEGF). VEGF functions as a potent permeability-inducing
agent, an EC chemotactic agent, an EC proliferative factor,
and an anti-apoptotic signal for ECs [35]. In the presence
of VEGF, unstable vessels survive in spite of their instability.
However, in the absence of VEGF, the upregulation of Ang-2
relative to Ang-1 destabilizes the coopted vessels within the
tumor and marks them for regression [33]. Vessel regression
in the absence of vessel growth leads to the formation of4 Computational and Mathematical Methods in Medicine
INPUT: Cell and vessel location in tissue region
while time < Tmax do
STEP1: Numerically solve system of PDEs
STEP2: Determine vessel response to PDE solution
STEP3: Evolve each automatoncell
STEP4: Apply treatment (if treatment is given at this time)
end while
Algorithm 1: Hybrid CA model of vascular tumor growth and treatment.
hypoxic regions in the tumor mass. Hypoxia induces the
production of VEGF, stimulating the growth of new blood
vessels.
The algorithm utilized in this manuscript is a slightly
modiﬁed version of the algorithm presented in [32]. Besides
these small modiﬁcations, which are detailed below, the
algorithm has also been adapted to account for the admin-
istration of a drug at predeﬁned time intervals. The skeleton
framework of the algorithm is summarized in Algorithm 1.
In Section 3.2, I will go into more detail about the treatment
protocol.
(i) Automaton cell generation. A Voronoi tessellation of
random points generated using the nonequilibrium proce-
dure of randomsequential addition of hard disks determines
the underlying lattice for the algorithm [31, 32]. Each
automaton cell created via thisprocedure represents a cluster
of biological cells. Assuming the tumor under consideration
is GBM (in which glial cells have an average diameter of
40μm[ 36]), each automaton cell is chosen to represent a
cluster of seven glial cells. This number is small enough
to give an average automaton cell diameter less than the
characteristic diﬀusion length of oxygen, but large enough
to keep the run-time of the algorithm manageable [32].
(ii) Healthy microvascular network. The blood vessel
network which supplies the cells in the tissue region of
interest with oxygen and nutrients must be generated. This
is done using a modiﬁcation of the Krogh cylinder model, a
modelofthecapillarynetworkwhichassumesthatcapillaries
are straight, parallel and uniformly spaced [37]. The random
analog proposed in [32] takes the idea of using parallel line
segments and randomizes it, subject to a set of biologically
inspired constraints. In particular, linear blood vessels are
sequentially attempted to be placed within the tissue region
ofinterest.A vesselcanonlybeaddedtothesystem,however,
if it is not too close to a parallel vessel, if it does not cause too
many vessels to intersect at one site, and if it vascularizes at
least one unvascularized cell [32].
(iii) Initialize tumor. Designate the automaton cell in the
center of the tissue space as a proliferative cancer cell. This
is equivalent to taking the nonmalignant cell in the center of
the tissue and endowing it with a malignant phenotype.
(iv) Tumor growth algorithm. Time is then discretized
into units that represent one real day. At each time step:
(1) Solve PDEs. The following previously-developed sys-
tem of partial diﬀerential equations [32]i sn u m e r i -
cally solved one day forward in time
∂v
∂t
= DvΔv + bvhi

h −
v2
Kv

−k0vrv0 +k−0rv − μvv,
∂a1
∂t
= ba1ei

pi + hi + ni


e0 −
a2
1
Ka

− k1a1ra0 +k−1ra1 − μa1a1,
∂a2
∂t
= Da2Δa2 + ba2ei

pi + hi +ni


e0 −
a2
2
Ka

+ ba2hi

h −
a2
2
Ka

− k2a2ra0 + k−2ra2 − μa2a2,
∂rv0
∂t
=− k0vrv0 + k−0rv,
∂ra0
∂t
=− k1a1ra0 + k−1ra1 − k2a2ra0 + k−2ra2,
∂rv
∂t
= k0vrv0 − k−0rv,
∂ra1
∂t
= k1a1ra0 − k−1ra1,
∂ra2
∂t
= k2a2ra0 − k−2ra2.
(1)
A schematic of the interactions between the growth
factors, receptors, ligands, ligand-receptor com-
plexes, and cell types represented in (1)i sp r o v i d e d
in Figure 1. In these equations, v represents the
concentration of VEGF, rv0 is the concentration the
unbound VEGFR-2, and rv is the VEGFR-2 receptor
bound by VEGF. Further, the concentration of Ang-1
is given by a1,o fA n g - 2i sg i v e nb ya2, of unoccupied
Tie-2 isgivenby ra0, of Tie-2 bound byAng-1 is given
by ra1, and of Tie-2 bound by Ang-2 is given by ra2.
For the three ligands (VEGF, Ang-1, and Ang-2) each
equation indicates that the protein is produced by
the appropriate cell type (with a carrying capacityComputational and Mathematical Methods in Medicine 5
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Figure 1: Schematic representation of system of PDEs given in (1), showing the interactions between growth factors, receptors, ligand-
receptor complexes, and cell types. The ligand VEGF is denoted by V,A n g - 1b yA1, and Ang-2 by A2. Curved arrows indicate the cell type
that produced the referenced protein (e.g., hypoxic cells produce VEGF and Ang-2, whereas ECs produce Ang-1 and Ang-2), and straight
arrows indicate the physiological response to ligand-receptor binding (e.g., VEGF binding to VEGFR-2 induces angiogenesis). Notice how
VEGF and Ang-2 diﬀuse in the extracellular space, whereas Ang-1 only acts locally.
term [38]), and that there is a linear decay term.
Both VEGF and Ang-2 diﬀuse, whereas Ang-1 does
not. This is because Ang-1 is produced by ECs, and
then acts in a paracrine manner upon these ECs [38].
Further, the source term of each protein depends
on the cell types that produce the protein. VEGF is
produced by hypoxic cells [38]( hi,w h e r eh stands
for hypoxia and the subscript i denotes that this is
an indicator function), Ang-2 is produced by ECs
associated with malignant tissue (this includes ECs
associated with proliferative cells p, necrotic cells n,
and hypoxic cells) and is also produced by hypoxic
cells [38], and Ang-1 is produced by ECs associated
with malignant tissue.
Foreachreceptor(VEGFR-2andTie-2),theequation
represents the association and dissociation of the
ligand-receptor complex. A complete list of variable
and parameter deﬁnitions is given in Table 1.D e t a i l s
onthestableﬁnitediﬀerenceschemeusedtosolvethe
diﬀerential equations are found in [32].
(2) Vessel Evolution. Checkwhether each vessel meets the
requirements for regression or growth. Vessels with a
concentration of bound Ang-2 six times greater than
that of bound Ang-1 regress [34], provided that the
concentration of bound VEGF is below its critical
value. Vessel tips with a suﬃc i e n ta m o u n to fb o u n d
VEGF sprout along the VEGF gradient.
(3) Nonmalignant Cells. Ahealthycellundergoesapopto-
sis if vessel regression causes its oxygenconcentration
to drop below a critical threshold. To simulate this,
I use the fact that the characteristic diﬀusion length
of nutrients in tissue is 250μm[ 19, 39], and I assume
that oxygen can only reach cells within this critical
distance from a blood vessel. Therefore, I suppose
thatifthedistanceofahealthycellfromabloodvessel
exceeds the distance lprolif = 250μm, then the oxygen
l e v e la tt h a tc e l li si n s u ﬃcient and the cell undergoes
apoptosis. Further, nonmalignant cells do not divide
in the model, which is a reasonable assumption for
GBM [40].
(4) Necrotic Cells. Tumorous necrotic cells are inert.
(5) Hypoxic Cells. A hypoxic cell turns proliferative if
it is within a distance of lprolif = 250μmf r o ma
blood vessel. This is equivalent to saying its oxygen
level exceeds a speciﬁed threshold [32]. Similarly, a
hypoxic cell turns necrotic if the oxygen level drops
below a speciﬁed threshold. This is implemented
by converting any hypoxic cell that is further than
ad i s t a n c eo flhyp = 1500μmf r o mav e s s e li n t o
a necrotic cell [32].
(6) Proliferative Cells.
(a) A proliferative cell turns hypoxic if its oxygen
level drops below a speciﬁed threshold, that is,
if it is further than a distance of lprolif = 250μm
from a blood vessel.
(b) If the oxygen level at a proliferative cell is
suﬃciently high, the cell may attempt to divide6 Computational and Mathematical Methods in Medicine
Table 1: Summary of variables and parameters used in the model.
Variable Deﬁnition
v(x, y,t) Concentration of VEGF (μM)
a1(x, y,t) Concentration of Ang-1 (μM)
a2(x, y,t) Concentration of Ang-2 (μM)
rv0(x, y,t) Concentration of unbound VEGFR-2 (μM)
ra0(x, y,t) Concentration of unbound Tie-2 (μM)
rv(x, y,t) Concentration of VEGFR-2 bound by VEGF (μM)
ra1(x, y,t) Concentration of Tie-2 bound by Ang-1 (μM)
ra2(x, y,t) Concentration of Tie-2 bound by Ang-2 (μM)
ei(x, y,t) EC indicator function
hi(x, y,t) Hypoxic cell indicator function
pi(x, y,t) Proliferative cell indicator function
ni(x, y,t) Necrotic cell indicator function
h(x, y,t) Concentration of hypoxic cells (μM)
PDE parameters Deﬁnition Value
Dv Diﬀusion coeﬃcient of VEGF Dv = 3.6 ×10−4 mm2/h
Da2 Diﬀusion coeﬃcient of Ang-2 Da2 = 3.6 ×10−4 mm2/h
bv Production rate of VEGF by hypoxic cells bv = 0.05h−1
ba1 Production rate of Ang-1 by ECs ba1 = 0.01h−1
ba2 Production rate of Ang-2 by ECs ba2 = 0.08h−1
ba2 Production rate of Ang-2 by hypoxic cells ba2 = 0.05h−1
μv Decay rate of VEGF μv = 0.001h−1
μa1 Decay rate of Ang-1 μa1 = 0.003h−1
μa2 Decay rate of Ang-2 μa2 = 0.002h−1
k0 Associationrate of VEGF/VEGFR-2 k0 = 46.8μM−1·h−1
k−0 Dissociationrate of VEGF/VEGFR-2 k−0 = 0.2268h−1
k1 Associationrate of Ang-1/Tie-2 k1 = 36μM−1·h−1
k−1 Dissociationrate of Ang-1/Tie-2 k−1 = 0.1332h−1
k2 Associationrate of Ang-2/Tie-2 k2 = 41.7μM−1·h−1
k−2 Dissociationrate of Ang-2/Tie-2 k−2 = 0.108h−1
Kv Carrying capacity of VEGF Kv = 10−2μM
Ka Carrying capacity of angiopoietins Ka = 1.5 ×10−2 μM
e0 Endothelial cell concentration per blood vessel e0 = 10−4 μM
Treatment parameters Deﬁnition Value
T1 AI treatment parameter is bv/T1 T1 = 10,100,1000
T2 Fraction of proliferative cells killed by cytotoxic agent T2 = 0.24,0.34,0.44
T3 Fraction of angiogenic vessels destroyed by VDA T3 = 0.1,0.3,0.6,0.9
into the space of a viable nonmalignant cell.
To determine the position of the daughter
cell, an intercellular mechanical stress growth
process is assumed [31]. In this process, the
new proliferative cell is placed in the position
of the dividing cell’s nearest neighbor. If this
cell is occupied (meaning if a cancer cell is
already locatedatthisnearestneighborsite),the
tumor cells are successively pushed outward,
eventually resulting in the presence of one
new proliferative automaton cell at the tumor
periphery.
(c) The probability that a proliferative cell divides,
pdiv,isinﬂuencedbythelocationofthedividing
cell from the tumor center (r), reﬂecting the
eﬀects of mechanical conﬁnement pressure
imposed by the skull. In particular, assuming
am a x i m u mt u m o re x t e n to fRmax (taken to be
10mm in the model) and assuming that me-
chanical conﬁnement pressure inhibits tumor
growth, gives the following equation for pdiv:
pdiv = p0

1 −
r
Rmax

. (2)Computational and Mathematical Methods in Medicine 7
Table 2: Dosing Schedule for Simulated Drugs.
Drug Dosing Schedule Therapeutic Levels?
AI Once every two
weeks
Maintained between
successive treatments
due to 20 day half-life of
drug [43]
Cytotoxic
Chemotherapeutic
Daily (up to 6
weeks in a row)
Maintained between
successive treatments
due to 1.8 hour half life
of drug [44]
VDA Once every
three weeks
Maintained only in a 24
hour window after drug
administrationdue to
4.2 hour half-life of drug
[45]
The base probabilityofdivision, p0,dependson
the distance of the cell to the nearest blood ves-
sel, dvessel. The average value of p0 was ﬁxed to
be 0.192 (corresponding to a cell doubling time
of approximately four days), with p0 taking on
a minimum value pmin of 0.1 and a maximum
value pmax of 0.284 [41]. This means that a
proliferative cell in the model can have a cell
doubling time anywhere in the range of three to
seven days.The formula used to determine p0 is
p0 =
pmin − pmax
lprolif
dvessel + pmax, (3)
where dvessel ≤ 250 since only well-oxygenated
cells can divide. Under this condition, p0 > 0.
(v) Apply treatment (if applicable on a particular day).
Importantly, the algorithm described above has been
s h o w nt ob ep r e d i c t i v e( 1 )w h e nat u m o rc a ni n i t i a t e
angiogenesis and (2) when angiogenesis cannot be initiated
[32]. In particular, it has been shown that, over an order of
magnitude in tumor radius, this algorithm can successfully
predicttumorsize andthepercentofproliferativecellsfound
in the tumor mass [31, 32]. Further, when a tumor cannot
initiate angiogenesis, the algorithm successfully predicts that
the tumorcannot grow beyonda microscopic size of 1-2mm
in diameter [32, 42].
3.2. Treatment Protocol. In the current manuscript, the goal
is to validate that the hybrid CAmodel canaccuratelypredict
the eﬃcacy of anumber of cancerdrugs. Once the model has
been shown to work on drugs of known eﬃcacy, the model
can then be used to predict the eﬃcacy of novel therapeutic
compounds.
The predictive abilities of the model will be tested using
both an angiogenesis inhibitora n dav a s c u l a rd i s r u p t i n g
agent. The simulated AI will be based on the previously-
discussed FDA-approved AI, bevacizumab. Bevacizumab is
a monoclonal antibody that binds to and inhibits VEGF
[43]. It has beendemonstrated that bevacizumab encourages
tumor shrinkage, increases progression-free survival times,
and improves overall survival in patients with recurrent
GBM [46, 47]. Given the success of phase II clinical trials,
bevacizumab has been approved (through an accelerated
process) for the treatment of GBM [48].
The second class of vascular-targeting agents I will
explore the eﬃcacy of are the VDAs. VDAs diﬀer from
AIs in that they selectively target the tumor vasculature for
destruction. The simulated VDA will be based on a com-
poundcurrentlybeingtestedinclinicaltrials, combretastatin
A4 phosphate (CA4P). CA4P is a prodrug that is rapidly
dephosphorylated to the active product tubulin inhibitor
CA4 [45]. In experimental tumors, CA4P administration
results in rapid and selective tumor-vascular damage. Within
one hour oftreatment time, blood ﬂow through the tumoris
reducedto levelsoflessthan 5%the starting value,leading to
the formation of large necrotic regions within the tumor [4].
Inorder to simulate drug delivery, a dosing strategy must
bechosen(seeTable2).Asdetailedbelow,thedosingstrategy
for the simulated AI and VDA will diﬀer signiﬁcantly in
order to accurately represent the use of these drugs in the
clinic. For both the simulated AI and VDA, I assume the
drug uniformly distributes itself throughout the vasculature.
It is then assumed that, just as with oxygen, any region
of tissue within a ﬁxed distance of a blood vessel has
equal access to the drug, but tissue regions further than
this critical distance receive insuﬃcient levels of the drug.
Implicit in this assumption is that the drug and oxygen have
t h es a m ed i ﬀusion length, which may or may not be the case.
Further, the assumption of a uniform spatial distribution
of the drug through the vasculature is not physiologically
accurate. It is well known that variations in the vascular
network and brain microstructure can impact drug delivery
[1, 3, 49]. Despite this, the mathematical model proposed
herein can still be used to diﬀerentiate between plausible
and implausible therapies. To elaborate, a treatment that is
not successful under this simpliﬁed condition has little to no
hope of working under less ideal circumstances, where the
drug is heterogeneously distributed throughout the tumor.
Treatments that appear to thwart tumor growth in this
simpliﬁed scenario are therefore plausible therapies that may
work in a heterogeneous environment. If a plausible therapy
is indeed identiﬁed, the spatial distribution of the drug can
be modeled more accurately.
Thefollowing treatmentscenarioswillbeanalyzedinthis
manuscript.
(i) AI in isolation. I will administer a bevacizumab-like
AI by inhibiting the production of VEGF (the bv
parameter in the model) by a factor of T1.( N o t e ,
I choose the notation Ti to stand for Treatment
parameter i. This notation should not be taken to
mean that all treatment parameters have the same
meaning/units.) I start with the assumption that the
treatmentparameterT1 takesonthevalueof100,and
I perform a sensitivity analysis of this parameter. The
AI in the simulation will be administered once every
two weeks [43]. This time interval has been chosen
because thehalf-life of bevacizumab is approximately8 Computational and Mathematical Methods in Medicine
20 days, with eﬀective concentrations being found
in the brain two to three weeks after administration
[43]. Thus, as a ﬁrst pass, I assume the AI is always
present at therapeutic concentrations in the brain, as
administration every two weeks should ensure this
occurs.
Importantly, the mode of action of the AI in the
model could be simulated in a number of other ways.
For instance, the AI could sequester unbound VEGF
and therefore limit the amount of VEGF available to
bind to VEGFR-2. This is equivalent to decreasing
k0, the the association rate of VEGF and VEGFR-2
in the model. Another way the AI could be modeled
is by reducing the response of ECs to the presence
of VEGF. This is equivalent to increasing the VEGF
threshold parameter rvcrit (see [32]).
(ii) AI with cytotoxic chemotherapy. For those tumor
types that it has been approved for, bevacizumab is
typically administered in combination with a cyto-
toxic chemotherapeutic that targets actively divid-
ing cells. Given that the mathematical model in
this manuscript was developed to study GBM, the
cytotoxic agent simulated will be the standard one
used for GBM care, temozolomide [50]. It has been
shown that a continuous administration schedule for
temozolomidecan be sustained forsix toseven weeks
[50]. Therefore, the cytotoxic chemotherapeutic in
the model will be administered daily for a six week
period of time, at which point the therapy will be
discontinued for safety reasons. Given that the half-
life of temozolomide is 1.8 hours [44], it can be
assumed that therapeutic concentrations of the drug
are maintained in the brain each day the cytotoxic
agent is administered. In the model, the cytotoxic
agent has a 34% chance (treatment parameter T2 =
0.34) of destroying an actively dividing cell each day
a therapeutic level is maintained in the brain. This
number was determined by considering the net cell
kill of temozolomide over ﬁve days of treatment in
mice harboring high-grade gliomas (measured to
be 0.4 log units [51]) and the daily growth rate
of GBM (using the fact that glioma cell doubling
time is approximately four days [31]). In calculating
this percent, I assumed the tumor is growing at an
exponential rate and that a set percent of cancer
cells are killed with each daily dose of chemotherapy
(see the appendix for details). The latter assumption
is referred to as the cell kill theory or fractional
kill hypothesis [52]. A sensitivity analysis will be
performed on T2, the cytotoxicity parameter value.
Further, for these simulations, the AI will be admin-
istered as described previously.
(iii) VDA in isolation. I will administer a CA4P-like VDA
by assuming that during each period of drug admin-
istration, thereis a 60% chance (treatment parameter
T3 = 0.6) the VDA destroys an angiogenic vessel.
Thisissimulating thefact thatVDAsselectivelytarget
blood vessels that grow via angiogenesis, and not the
coopted vessels. Although this parameter value has
been arbitrarily assigned, a sensitivity analysis will
be performed for 0.1 ≤ T3 ≤ 0.9. The maximum
value of T3 = 0.9 is based on the fact that, for in
vivo studies of human breast cancer models in which
there was systemic drug delivery, functional vascular
volume was reduced by 93% at six hours following
drug administration [53]. Therefore, the value of
93% must be a strict upper bound on the eﬃcacy
of a VDA for clinical tumors growing in vascular
environments, as drug eﬃcacy in clinical tumors is
limited by the tumor microenvironment.
In Phase I clinical trials, CA4P was administered
intravenously once every three weeks [45]. The half-
lifeoftheprodrugCA4Pwas0.47hours,andthehalf-
life of the active CA4 was 4.2 hours [45]. Therefore,
unlike with the AI, the simulated drug cannot be
assumed to always be present at therapeutic concen-
trations in the brain. Further, preclinical studies have
demonstrated that CA4P achieves maximal vascular
shutdown at four to six hours after exposure and
sustained activity for up to 24 hours [45]. Thus, as
a ﬁrst pass at modeling VDA administration, the
simulated drug will be administered once every three
weeks, and the drug will only exert its eﬀects on the
vasculature the day that it is administered.
For each of the treatments (whose parameters are
summarized in Table 1 and whose dosing schedules are
summarized in Table 2), 10 simulations will be run and
the average tumor response to the drug will be reported.
Each treatment is applied once the tumor reaches the
critical size of 4mm in radius. For each of the therapeutic
regimens, a sensitivity analysis of the treatment parameter(s)
will also be performed. All simulations were run on a
computational cluster consisting of 26 dual Opteron 248
nodes with 2GB RAM and a processor speed of 2.2GHz.
The simulations described herein (of at least one year of
physical tumor growth) took anywhere from 45 minutes to
80 minutes to complete. In the visualizations of the tumor
that will be shown, the following convention is utilized:
viable nonmalignant cells are labelled white, nonmalignant
cells that have undergone apoptosis are green, necrotic
tumor cells are black, nonproliferative/hypoxic tumor cells
are yellow, and proliferative tumor cells are blue. Further, in
the visualisation of the vasculature, the following convention
is used: vessels that are originally part of the healthy tissue
vascular network are labelled red, and vessels that grow via
angiogenesis are labelled purple.
4.Resultsand Discussion
4.1. AI in Isolation. As described in the treatment protocol,
the ﬁrst therapy tested is the administration of an AI such
as bevacizumab. In Figure 2, I show the antitumor activity
of the AI, as compared to the case where no treatment
is utilized. In particular, I show the tumor area as a
function of time (Figure 2(a))a n dt h ea c t i v et u m o ra r e aComputational and Mathematical Methods in Medicine 9
(meaning, thearea oftheproliferativeandhypoxicregionsof
the tumor—Figure 2(b)), bothaveraged over10 simulations.
By comparing the growth of the entire tumor mass with AI
treatment and without (Figure 2(a)), a clear decrease in the
rate of tumor expansion is observed. Further, when looking
only at the area of the active tumor region (Figure 2(b)),
it is observed that this region essentially stabilizes, with no
measurable growth or shrinkage after drug administration.
Therefore, despite the extreme decrease in active tumor
growth rate, the active tumor region is not eliminated by
AI treatment. This observation is conﬁrmed by looking at
simulated images of an AI-treated tumor (Figure 3). In this
ﬁgure, it can be seen that AI administration leaves a number
of hypoxic and proliferative cells remaining at the tumor
periphery, and this active region leads to slow growth of
the tumor mass observed in Figure 2(a).T h es u r v i v a lo f
active tumor cells and the resulting slow growth is largely
a consequence of the fact that the tumor grows in a well-
vascularized environment, highlighting the important role
the microenvironment plays in treatment response.
The results shown in Figures 2 and 3 were all obtained
by decreasing the production rate of VEGF to simulate
AI action. Two other modes of AI action, decreasing the
association rate of VEGF/VEGFR-2 and reducing the sensi-
tivity of ECs to the presence of VEGF, were also considered.
The growth curves that resulted from the three modes of
action were very similar (data not shown). Decreasing the
production rate of VEGF did prove to be slightly more
eﬃcacious than the other implementation strategies, and,
hence, why this mode of action was used throughout the
manuscript.
A sensitivity analysis of the treatment parameter reveals
thata bevacizumab-likedrugwill leadto asigniﬁcant clinical
response at all levels of inhibition tested, although the larger
the eﬃcacy of the AI, the more measurable the antitumor
activity (Figure 4). In fact, when the most eﬃcacious AI is
administered (T1 = 1000), only approximately 1% of the
active cell population remaining after eight months of AI
treatment are proliferative cancer cells. In other words, this
highlyeﬃcaciousAIhasalmostentirelyreducedthetumorto
amass ofhypoxiccells;throughthismass doesmaintain slow
growth due to the surviving population of proliferative cells.
Whether this level of drug eﬃcacy is clinically achievable is
not clear.
The eﬀects of AI administration predicted by the model,
particularly for T1 = 10 and 100, are in good agreement
with clinical data [5]. Clinical observations revealed that
when a patient is treated with bevacizumab, initial transitory
improvements are observed, just as the simulations show
a signiﬁcant decrease in the rate of tumor expansion (Fig-
ure 2). However, in spite of these transitory improvements,
clinical tumors are observed to continue growing, just
as is seen in the simulations (Figures 2 and 3). Several
mechanisms have been implicated in the apparent acquired
resistance to bevacizumab. One hypothesis is that angiogenic
t u m o r sc a ne v o l v ei nt h ep r e s e n c eo fa nA I .F o ri n s t a n c e ,
evidencesuggests that if one part of the angiogenic cascade is
blocked, it can compensate by activating alternative proan-
giogenic pathways [5]. Other compensatory mechanisms
tumors have developed to bypass the angiogenic blockade
imposedbyanAIincluderecruitingproangiogeniccellsfrom
bone marrow and activation/enhancement of invasion [5],
which gives cancer cells access the normal tissue vasculature
and makes them less dependent on the angiogenic blood
supply.
While it is plausible that any or all of these mechanisms
may lead to compensatory angiogenesis in clinical tumors,
the simulations suggest that a tumor growing in a vascular
environment can continue to grow during AI administra-
tion, even without the previously-mentioned compensatory
angiogenic mechanisms. Given thatthe currentimplementa-
tion of the model does not incorporate alternative pathways
that trigger angiogenesis and does not include the bone
marrow orinvasion, thismay explain why themodel predicts
slow continuing growth instead of the more accelerated
growth observed in patients. However, it still reveals a very
important characteristic of AI treatment: innate limitations
in AI treatment, and not acquired resistance, may be a
limiting factor in using AIs as a single front line cancer treat-
ment. While researchers are currently working to develop
angiogenic drug cocktails that target diﬀerent angiogenic
pathways (with the aim of preventing regrowth), such a drug
cocktail may still suﬀer from the same downfall as a single
AI – slow growth at the tumor periphery can persist when
u s i n ga nA Ii ni s o l a t i o n ,i np a r ticular for tumors growing in
a well-vascularized environment.
4.2. AI with Cytotoxic Chemotherapy. My analysis of admin-
istering an AI in isolation shows that it can signiﬁcantly
hinder tumor growth, but it cannot eliminate the active
tumor region and, therefore, slow tumor growth persists
despite drugadministration. However, it is not common that
an AI (or a combination of AIs) would be the only form of
therapy used to treat cancer. Traditional forms of therapy,
including cytotoxic chemotherapy and radiation, are still
usedforessentially allcancerpatients,providedthatapatient
can physically withstand the treatment. Although it may
seem counterintuitive to administer an AI and a cytotoxic
chemotherapeutic simultaneously, as interfering with the
tumor vasculature would seem to interfere with the delivery
of the chemotherapeutic, this is common clinical practice.
The wisdom of this approach is something that I will explore
further in future work. Currently, I will focus on analyzing
the eﬃcacy of administering an AI like bevacizumab in
combination with a standard cytotoxic chemotherapeutic
liketemozolomide.InFigure2, Ishowthe averageantitumor
activity of a treatment protocol that involves administering
an AI every two weeks for a nine month period of time,
coupled with the daily administration of a cytotoxic agent
for a six week period of time.
As Figure 2 shows, the combination of an AI and a
cytotoxic agent has more antitumor activity than the admin-
istration of an AI in isolation. Overall tumor growth occurs
at a slower rate, and the active tumor region actually shrinks
while the cytotoxic therapy is being applied. In order to
understand why the cytotoxic agent has this additive eﬀect
when administered with an AI, it is useful to refer to10 Computational and Mathematical Methods in Medicine
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Figure 2: (a) Average area of tumor region and (b) average area of active tumor region, both compared for four diﬀerent scenarios: no
therapy is administered, AI administration only, AI with cytotoxic chemotherapy and VDA administration only.
(a) (b)
(c) (d)
Figure 3: Snapshotsof a tumor treated with an AI only. (a) Tumor after two months of growth, before treatment is applied. (b) Tumor after
four months of growth, two weeks after treatment is ﬁrst administered. (c) Tumor after eight months of growth, 19 weeks after treatment is
ﬁrst administered. (d) Tumor after one year of growth, 37 weeks after treatment is ﬁrst administered.Computational and Mathematical Methods in Medicine 11
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Figure 4: Sensitivity analysis of the AI treatment parameter. The
treatment parameter was tested over two orders of magnitude,
and the average area of the active tumor region predicted by the
algorithm is shownfor each parameter value.
the snapshots of the simulated tumor shown in Figure 3.
When an AI is applied in isolation, a small number of
proliferative cancer cells survive at the tumor rim. These
proliferative cells mainly obtain their oxygen and nutrients
from the vasculature of the healthy tissue that surrounds the
tumor mass, although some angiogenic vessels also supply
the tumor. The addition of a cytotoxic agent that targets the
actively dividing cells leads to the death of the proliferative
cells found at the tumor periphery, and this is what causes
thedecrease inthe activetumorarea observedinFigure2(b).
T h ed e c r e a s ei na c t i v et u m o ra r ea is only maintained during
the cytotoxic agent treatment window.
A sensitivity analysis of both the AI parameter (T1)a n d
the cytotoxicity parameter (T2) has also been performed. I
ﬁrst focus on the case where I ﬁx the cytotoxicity parameter
at T2 = 0.34 and vary the AI parameter (Figure 5(a)).
Simulations reveal that during the cytotoxic chemotherapy
treatment window, the AI parameter T1 does not have
a signiﬁcant impact on the rate of decline of the active
tumor area. In other words, when coupled with an eﬀective
cytotoxic agent, the action of the cytotoxic agent drives
tumor response more so than the action of the AI. In
fact, the rate of decrease in active tumor area during
cytotoxic drug administration is comparable whether no
AI is given, or whether the AI is administered at very
high concentrations. Therefore, it seems that there is little
clinical beneﬁt for administering an AI at the same time a
cytotoxic agent is being administered. However, the AI still
adds signiﬁcant clinical beneﬁt to standard a chemotherapy
regimen, as it does drastically control the rate of tumor
expansion after removal of the cytotoxic agent (Figure 5(a)).
Finally, it should be noted that if the tumor mass contains
a chemo-resistant population (i.e., a population of cells
that do not respond to the cytotoxic agent), simulations
reveal that there is a small clinical beneﬁt to administer-
ing an AI during the cytotoxic agent treatment window
(data not shown).
Shifting to the case where the AI parameter is ﬁxed
at T1 = 100, and the cytotoxicity parameter T2 varies
(Figure 5(b))s h o w st h a tT2 controls the rate of decline of
the active tumor area when the treatment is ﬁrst applied,
b u th a sn oi m p a c to nt h er a t eo fa c t i v ea r e ar e g r o w t hu p o n
removal of the cytotoxic agent. In fact, after 7 months oﬀ
of the cytotoxic chemotherapy, the active tumor area almost
catches up to the active tumor area when no cytotoxic agent
wasused.Thissuggeststhatacytotoxicagentcantemporarily
shrink a tumor mass, therefore alleviating symptoms and
possibly improving quality of life. However, this combined
treatment strategy is no more eﬀective in the long-term than
applying an AI in isolation.
I fw ef o c u so u ra t t e n t i o no nt h em o s te ﬃcacious treat-
ment parameters, T1 = 1000 and T2 = 0.44, we observe that
disease stabilization can be achieved if the AI continues to
be administered once every two weeks following the removal
of the chemotherapeutic (see Figure 6(a),t i m e ≤ 475
days). However, there have been reports of serious and life-
threatening bleeding in patients treated with bevacizumab
[54], so this drug cannot be administered indeﬁnitely.
Therefore, I ran further simulations to determine tumor
response after AI removal. To simulate this scenario, the
AI is removed after one year of treatment. As can be
seen in Figure 6, cessation of AI treatment restimulates
tumor growth, as the energy supply of dormant cells is
replenished once angiogenesis is reinitiated. Therefore, the
algorithm leads to the important conclusion that even a
highly eﬃcacious AI, which can lead to disease stabilization,
cannot prevent a tumor from regrowing upon cessation
of therapy. This points to an inherent limitation in using
AIs, even with cytotoxic chemotherapy, as a front-of-the-
line cancer drug, at least for tumors growing in a vascular
environment.
4.3. VDA in Isolation. Several vascular disrupting agents are
currently undergoing testing in preclinical and clinical trials
[4]. Although various mechanisms can be utilized to both
target and disrupt the vasculature, the net eﬀect of these
drugs is to halt blood ﬂow through the tumor vasculature
and give rise to a widespread pattern of central necrosis [4].
In my simulations, I have used a generic VDA that shuts
down the blood ﬂow in the angiogenic vasculature, similar
to the actions of the VDA CA4P.
As noted previously, VDAs are typically used in an
intermittent fashion over shorter periods of time than an AI.
Forthisreason, theVDA inthesimulations wasadministered
every three weeks, and because of the short half-life of CA4,
the drugs action takes place only during the day the drug
was administered. The eﬀects of applying the VDA (when
the vessel destruction parameter is T3 = 0.6) as described
over a nine-month period of time can be seen in Figure 2.A s
with the other treatments, the VDA does limit tumor growth
relative to applying no treatment whatsoever. However, the
eﬀects are not as promising as the other treatments tested.12 Computational and Mathematical Methods in Medicine
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The area of the active tumor region continues to grow, albeit
at a slower rate than when the VDA is not administered.
In order to better understand tumor response to VDA
treatment, in Figure 7(a) I have plotted the active tumor
area as a function of time for a single tumor treated with
aV D A( T3 = 0.6). This analysis shows that each day the
VDA is administered, the active tumor area decreases for
approximately one week. However, because this rapid vessel
loss triggers massive amounts of hypoxia within the tumor,
strong angiogenic signals are sent into the environment.
The resulting angiogenesis causes the active tumor area to
increase once again, and after only two weeks of applying the
VDA, the active tumor area is typically restored to what it
was before the previous treatment was applied. Therefore,
given the time scales for angiogenesis in the model, I can
conclude that administering a VDA once every three weeks
is insuﬃcient to maintain steady tumor growth inhibition.
The above observation explains the oscillatory behavior
seen in the active tumor area plot (Figure 7(a)). However,
it does not fully explain why the steady oscillations do not
drastically limit active tumor size in the long-term. In order
to fully understand the ineﬀectiveness of the VDA, it is
useful to look at snapshots of the tumor directly preceding
(Figure 7(b)) and proceeding (Figure 7(c))V D Aa d m i n i s t r a -
tion. Before VDA administration, the tumor is vascularized
by both coopted (shown in red) and angiogenic (shown in
purple) blood vessels. After applying the VDA, the majority
oftheangiogenicvesselsarelostinthetumormass. However,
because VDAs work by selectively binding to angiogenic
vessels, the coopted vessels in the tumor are not destroyed
by VDA administration. Therefore, proliferative cancer cells
that receive oxygenand nutrients via the cooptedvasculature
survive at the tumor periphery, and these cells maintain the
growth of the tumor, just as seen in preclinical trials [4, 55].
Therefore, Ihavefoundthatthecombinationofangiogenesis
occurring between treatments, and slow growth occurring at
the tumor periphery, greatly limits the antitumor activity of
the simulated VDAs.
It is natural to ask whether the VDA being used in
the simulations is not destroying enough angiogenic blood
vessels (with T3 = 0.6), and if this is partially responsible
for the low antitumor activity of the simulated VDA.
Therefore, a sensitivity analysis was performed on T3,t h e
VDA treatment parameter (Figure 8). Surprisingly, I ﬁnd
that increasing the VDA parameter beyond T3 = 0.3h a s
no measurable impact on the active tumor area. While this14 Computational and Mathematical Methods in Medicine
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may seem improbable, it can be explained by understanding
how vessel regression works in the algorithm. Each edge
of the lattice that contains an angiogenic vessel is checked
to see if it regresses. If regression occurs, not only does
that “edge” of the vessel get destroyed, but any lattice edges
that are upstream of that edge also get destroyed. In other
words, if you kill the source of blood, any vessels that only
receivedbloodfromthatsourcearealso eﬀectivelydestroyed.
This creates the relative insensitivity to changes in the VDA
parameter T3. It is worth noting that if the VDA parameter
is made suﬃciently small (T3 = 0.1), the tumors grow at a
noticeably faster rate than for T3 ≥ 0.3.
5.Conclusions
A previously validated mathematical model has been utilized
to make predictions on the eﬃcacy of certain vascular-
targeting drugs. Three preclinically and/or clinically tested
treatment protocols were analyzed, and simulation data was
found to be in good agreement with the data collected
from these trials. In particular, the antitumor activity of
an angiogenesis inhibitor such as bevacizumab was well-
predicted: there is an initial period of growth inhibition,
but in the long-term, tumor regrowth occurs. The addition
of a cytotoxic chemotherapeutic led to increased antitumor
activityandwasthemosteﬀectivetreatmenttested.However,
removing all drugs after one year of treatment restimulates
tumor growth, suggesting that a protocol of an AI and a
cytotoxic agent can increase progression free survival times,
but cannot prevent long-term regrowth. The model also
made predictions on the eﬃcacy of a CA4P-like vascular
disrupting agent that agreed with preclinical observations
on the antitumor activity of VDAs. In particular, in spite
of VDA administration, a rim of proliferative cells survive
at the tumor periphery, and these, along with angiogenic
activity in between drug administration, maintain steady
tumor growth. The predictions made are highly dependent
on the vascular nature of the tumor microenvironment, in
which vessel cooption occurs alongside angiogenesis.
Taken together, simulation and clinical data strongly
suggest that vascular-targeting drugs, as currently admin-
i s t e r e d ,c a n n o tl e a dt oc a n c e re r a d i c a t i o n .H o w e v e r ,l o n g -
term control may be possible, for instance, when a highly
eﬃcacious AI (T1 = 1000) is administered with a cytotoxic
chemotherapeutic. While it certainly seems more desirable
to eradicate an entire tumor mass, as compared to simply
keeping the tumor at bay, recent work by Gatenby and
colleagues suggests otherwise [56, 57]. In particular, taking
lessonsfrombothappliedecologyandmathematicalmodels,
theysuggestthattherapeuticstrategiesthataimtomaintaina
stable,tolerabletumorvolumehaveabetterchanceofsuccess
than those therapies that aim to maximize tumor killing. In
this light, AIs may present themselves as a very important
therapy. It still remains to be seen, however, whether this
proposedparadigmshift will turnouttobeamoresuccessful
way to treat cancer patients, or if maximizing cancer cell
death is still the optimal way to proceed.
Any mathematical model has shortcomings that limit
predictability, and some of the proposed model weaknesses
warrant mentioning. One weakness is that there is only
one pathway that leads to angiogenesis in the simulated
tumors. In reality, there are many angiogenic pathways
(although the VEGF pathway accounted for here is the
dominant one) and treating a tumor with an AI that
targets one pathway can cause a compensatory angiogenic
response in the other pathways. In other words, unlike
in my simulations, angiogenesis can occur in real tumors,
even if the VEGF pathway is completely knocked down.
Therefore, my simulations predict that less angiogenesis is
occurring during AI administration than is likely the case.
In spite of this shortcoming, the model is still able to
identify an important feature of tumor growth in a vascular
environmentduringAItreatment:thetumorscansurvivevia
thecooptedvasculature,andslowgrowthismaintained. This
suggests that drug cocktails that target multiple angiogenic
pathways [5] may be able to slow tumor regrowth, but could
not fully inhibit tumor expansion.
Anothershortcoming ofthe model is the nature in which
blood is delivered to the tumor and how oxygen and drugs
are distributed throughout the tumor mass. First of all, the
model does not consider blood ﬂow through the capillary
network. This important modeling consideration has been
taken up by other authors (see, e.g., [58–60]). Instead of
modeling the details of blood ﬂow, I have made the simpli-
fying assumption that any cell within a ﬁxed distance from a
vessel receives an adequate supply of oxygen and drugs. This
idealization ignores the fact that angiogenic blood vessels are
leaky and may not homogeneously distribute oxygen and
drugs throughout the tumor [1, 3]. Interestingly enough,
despite the idealizations made, I have still been able to
illustrate the failure of a number of treatment protocols. As
future work, modiﬁcations can be made to improve the way
in which drug transport and distribution are modeled. For
instance,bloodﬂowcanbedirectlysimulatedor“pinknoise”Computational and Mathematical Methods in Medicine 15
(i.e., a bandwidth-limited uncertainty) could be utilized to
simulatethepartiallystochasticvariationsinvascularuptake.
Another approach would be to couple a pharmacokinetic
model of drug delivery and distribution with the hybrid
cellular automaton model of tumor growth.
Finally, the model also assumes that there is a uniform
phenotypic proﬁle of cells within a tumor mass, which is
never really the case. In future work, the model can be
expandedupontoincorporate bothinterpatient and intertu-
mor genotypic/phenotypicvariability [41]. Further, not only
is there phenotypic variability within a tumor, treatment can
induce new mutations to occur in a cancer. In the future, the
model will be expanded upon to incorporate the treatment-
induced mutations.
To conclude, I have illustrated that the model can
successfully predict, without any a priori knowledge, the
antitumor activity of a number of vascular-targeting treat-
ment protocols. The tumor microenvironment was shown
to play an important role in drug activity. The predictions
made by the model were veriﬁed by comparing to preclinical
and clinical data wherever possible. The fact that the model
could lead to predictions comparable to those made in
preclinical and clinical trials is rather important. In order
for clinical trials to reach these conclusions, millions of
dollars were spent, many years of time were invested, and
patients were put at risk of having an adverse response
to the treatment. The work done herein illustrates that
mathematical models can be used to test the eﬃcacy of
cancer drugs and, importantly, rule out drugs that will not
have signiﬁcant antitumor activity. In the future, I will use
the mathematical model to test the eﬃcacy of administering
adrugcocktailofan AIand VDA,in an eﬀorttolearnifthere
are additiveeﬀectsofcombining thesetwovascular-targeting
agents. I also plan to exploit the predictive abilities of the
model to search for a treatment protocol that maximizes
active tumor death, in the hopes of identifying a treatment
that can cause permanent tumor growth inhibition.
Appendix
EstimatingCytotoxicityParameterT2
The cellkill theory proposesthata set percentofproliferative
cancer cells are killed with each dose of chemotherapy [51].
The log cell kill L is used to measure this percent
L = log10

Vpre
Vpost

,( A . 1 )
where V is tumor volume, “pre” represents a pretreatment
measurement, and “post” represents a posttreatment mea-
surement. Assuming each cell has a ﬁxed volume, it is
straightforward to see that
L = log10

Npre
Npost

,( A . 2 )
where N is thenumber ofcells in thetumor. Solving for Npost
gives
Npost =
Npre
10L . (A.3)
In [51], mice were treated with temozolomide for ﬁve
days. The log cell kill was calculated to be 0.4 log units.
In order to use this information to determine the value of
T2 (the percent of proliferative cells killed by temozolomide
eachdayitisadministered),Iassume thatthenumberofcells
at time t is proportional to the number of cells at time t − 1,
g i v i n gt h ed i s c r e t er e l a t i o n s h i p
N(t) = ktNpre, (A.4)
where k is the growth proportionality constant. Using L =
0.4 and relationships (A.3)a n d( A.4), I ﬁnd that after t = 5
days of treatment
Npost = N(5) = k5Npre =
Npre
100.4, (A.5)
which corresponds to k satisfying
k =

2
5
1/5
≈ 0.83255. (A.6)
Therefore, thefraction ofcellslostperday(lookingatthe
net eﬀect of growth and death) is 1 − k ≈ 0.16745, meaning
the killing rate is α =− 0.16745.
For GBM, the cell doubling time has been estimated to
be approximately four days [31, 40]. Assuming exponential
tumor growth, the growth rate of the tumor r can be
calculated using the relation
N(t) = Npreert. (A.7)
Using the fact that the cell doubling time is approximately
four days gives r ≈ 0.17563 as the expected growth rate. I
can therefore represent the rate of cell lose per day as
α = r −T2 ⇐⇒ net growth = rate of growth − killing rate.
(A.8)
This implies that T2 = 0.343, and, therefore, I use
T2 = 0.34 as the baseline value for the cytotoxicity of
temozolomide.
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